Momenta Pharmaceuticals (NASDAQ: MNTA) has recently received a number of price target changes and ratings updates:

  • 10/11/2017 – Momenta Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Momenta’s sales of Glatopa 20mg continue to do well and have captured approximately 40% of the market in the U.S. We are pleased with the company’s efforts to develop biosimilars given the potential in the market with recent approvals. In addition, a potential approval of M923 will boost investor confidence. The company has collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates. However, the ANDA approval for Glatopa 40mg is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, shares of the company have underperformed the industry in the last six months. The recent FDA approval of Mylan's generic version of Copaxone 40mg led to significant plunge in the share price.”
  • 10/6/2017 – Momenta Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/6/2017 – Momenta Pharmaceuticals was downgraded by analysts at Robert W. Baird from a “buy” rating to a “hold” rating. They now have a $15.00 price target on the stock, down previously from $22.00.
  • 10/5/2017 – Momenta Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $14.00 price target on the stock, down previously from $18.00.
  • 10/5/2017 – Momenta Pharmaceuticals had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $14.00 price target on the stock.
  • 10/4/2017 – Momenta Pharmaceuticals had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $15.00 price target on the stock, down previously from $22.00.
  • 10/4/2017 – Momenta Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock. According to Zacks, “Momenta’s sales of Glatopa 20mg continue to do well and have captured approximately 40% of the market in the U.S. We are pleased with the company’s efforts to develop biosimilars given the potential in the market with recent approvals. In addition, a potential approval of M923 will boost investor confidence. The company has collaborated with Mylan to develop, manufacture and commercialize six of its current biosimilar candidates. The progress with the autoimmune portfolio is also impressive However, the ANDA approval for Glatopa 40mg is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Shares of the company have outperformed the industry in the last twelve months.”
  • 10/4/2017 – Momenta Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $16.00 price target on the stock, down previously from $17.00.
  • 9/28/2017 – Momenta Pharmaceuticals is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “neutral” rating and a $18.00 price target on the stock.
  • 8/22/2017 – Momenta Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Momenta Pharmaceuticals, Inc. (MNTA) traded up 1.17% during trading on Thursday, hitting $12.95. The company had a trading volume of 255,138 shares. The company’s 50 day moving average price is $16.44 and its 200-day moving average price is $15.79. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.75 and a 1-year high of $19.90. The stock’s market capitalization is $959.03 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The business had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. During the same period last year, the company earned ($0.31) EPS. Momenta Pharmaceuticals’s revenue for the quarter was down 10.8% compared to the same quarter last year. On average, analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.50) EPS for the current year.

In other news, President Craig A. Wheeler sold 35,667 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the sale, the president now directly owns 286,121 shares in the company, valued at approximately $5,444,882.63. The sale was disclosed in a filing with the SEC, which is available through this link. Also, President Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $15.07, for a total value of $62,028.12. Following the completion of the sale, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 79,663 shares of company stock worth $1,414,498. 4.40% of the stock is owned by corporate insiders.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Receive News & Ratings for Momenta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.